Investors

Press Releases

Cardiol Therapeutics Reports 2018 AGM Results

June 13, 2019

Cardiol Therapeutics to Webcast Annual General Meeting on June 12

June 10, 2019

Cardiol Therapeutics’ Pharmaceutical Partner Noramco Presents at U.S. FDA Public Hearing on CBD

June 03, 2019

Cardiol Therapeutics Commences Trading on the OTCQX

May 30, 2019

Cardiol Therapeutics Announces Filing of Year-End Financial Statements and MD&A

March 28, 2019

Cardiol Therapeutics to Present at the 2019 LD Micro Virtual Conference

March 12, 2019

Cardiol Therapeutics Appoints Thomas Moffatt as Chief Commercial Officer

March 06, 2019

Cardiol Therapeutics Inc. Closes Over-Allotment

January 18, 2019

Cardiol Therapeutics Completes Initial Public Offering and the Company’s Common Shares and Warrants Commence Trading on the Toronto Stock Exchange Under the Symbols “CRDL” and “CRDL.WT”

December 20, 2018

Cardiol Therapeutics Appoints Mr. Chris Waddick as Chief Financial Officer, Ms. Anne Tomalin as Director of Regulatory Affairs, and Ms. Dolly Kao as Intellectual Property Counsel

August 30, 2018